Bharat Biotech said on Thursday that its corona vaccine BBV152 (Covaxin) is safe, well tolerated and immunogenic for children aged 2-18 years in the trial. The company said that this has come to the fore in the second and third phase of the vaccine study.

Bharat Biotech said that the company had conducted open-label trials at several centers in the second and third phases. In this, a trial was conducted on healthy children aged 2-18 for the safety, response and immunogenicity of Covaccine.

Vaccine is safe and effective

Krishna Ella, MD and Chairman, Bharat Biotech said, “The results of Covaxin trials in children are very encouraging. Vaccine protection is very important in children. We are happy to report that Covaxin has proven to be safe and immunosuppressive for children. We have now achieved our goal of developing a safe and effective COVID vaccine for adults and children.

Trials of Covaxin in children were conducted between June-September 2021. In the trial it was found to be safe, reactive and immune. Its data was given to the Central Drugs Standard Control Organization (CDSCO) in October. After this DCGI approved Bharat Biotech’s Covaxin for emergency use.

According to Bharat Biotech, the study did not show any serious side effects in children. Mild or severe symptoms were observed in 374 children. Of these, 78.6% were cured within a day. It has been said in the statement that complaints like pain were found in most of the children at the place of giving the vaccine.